Proposal to Increase Federal Tobacco Tax by 19% in Pakistan Budget

Regulations by 2FIRSTS.ai
May.28.2024
Proposal to Increase Federal Tobacco Tax by 19% in Pakistan Budget
Pakistan government considers increasing federal excise tax on tobacco in upcoming budget to reduce health burden. WHO supports higher tax rates.

According to a report from Pakistan's Business Recorder on May 28, the Pakistan government may increase the federal excise duty (FED) on tobacco in the upcoming budget for the fiscal year 2024-25. The World Health Organization (WHO) and the Ministry of Health have also recommended increasing the FED tax rate to more effectively reduce the health burden associated with tobacco consumption.

Proposal to Increase Federal Tobacco Tax by 19% in Pakistan Budget

 

According to a news report from 2024, the Ministry of Finance is expected to raise tax rates in the 2024 Finance Bill. One proposal being considered is to increase the federal excise tax on tobacco by 19%, despite recommendations from the World Health Organization (WHO) and the Ministry of Health to raise tobacco taxes by 37% and 20% respectively. The Federal Board of Revenue (FBR) in Pakistan has proposed to increase the federal excise tax on tobacco in the next fiscal year. During a budget preparation meeting between the FBR and various tobacco manufacturers, the latter expressed strong dissatisfaction with decreased production and increased domestic smuggling/illegal products.

 

The World Health Organization recommends increasing the federal consumption tax by 37% to bring the tax share of retail prices to the international standard of 70%. Various anti-smoking activists have submitted tax proposals to the Ministry of Health, including the WHO's recommendation, stressing that raising tobacco taxes can not only ease the burden on the healthcare system but also help increase revenue.

 

According to the tax proposal, maintaining the current federal consumption tax rate could lead to a decrease in health recovery. In order to achieve the same level of health cost recovery observed in 2023-24, the federal consumption tax rate would need to be increased by 37% next year. This would help generate an additional 600 billion rupees in goods and services tax from tobacco.

 

The cost of tobacco consumption on the healthcare system indicates that there are currently 31.6 million adults in the country using tobacco, resulting in over 160,000 deaths per year. The cost of smoking-related diseases and deaths accounts for at least 1.4% of the country's GDP.

 

From July 2023 to January 2024, tax revenues have reached 122 billion rupees (approximately 1.4 billion US dollars), with the full year's income expected to exceed 200 billion rupees (approximately 2.4 billion US dollars). The tax proposal suggests that increasing tobacco product taxes will help save lives, and the government should consider incorporating automatic adjustments to consumption taxes in the tobacco tax strategy for the next fiscal year 2024-25 to ensure it covers a certain percentage of the overall health costs associated with smoking.

 

The latest policy report "Restoring Medical Expenses, Saving Lives" suggests that the Social Policy Development Center (SPDC) is recommending a 37% increase in federal consumption tax in the next fiscal year budget. The Campaign for Tobacco-Free Kids (CTFK) has proposed a 26.6% increase in federal consumption tax for the 2024-25 fiscal year.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
A 12-week European Commission consultation on revising the Tobacco Products Directive and Tobacco Advertising Directive is due to close on Aug. 14, 2026. The Commission has identified e-cigarette flavours, disposable vapes, tobacco heating devices, nicotine pouches, nicotine-free e-cigarettes, packaging and digital marketing among areas for possible new EU rules. National regulations already vary significantly across the bloc, a fragmentation the Commission says creates internal-market barriers and distorts competition. No formal revised TPD/TAD legislative text has yet been published, with the Commission currently indicating December 2026 for the legislative initiative.
Aug.14